Sleep and circadian disruption represent one of the most promising yet underexploited therapeutic intervention points in neurodegenerative disease. The bidirectional relationship between neurodegeneration and circadian dysfunction creates a self-reinforcing pathological cycle: neurodegenerative pathology damages sleep-regulating circuits, while impaired sleep accelerates pathological protein accumulation through failure of glymphatic clearance and other mechanisms. This synthesis evaluates therapeutic approaches targeting the sleep-circadian axis, including melatonin signaling, orexin modulation, light therapy, and chronotherapeutic strategies, with investment prioritization based on mechanism strength, clinical evidence, and pipeline maturity.
Melatonin acts through MT1 and MT2 receptors to regulate circadian rhythm, provide antioxidant effects, and modulate neuroinflammation. The pathway has gained significant attention following recent discoveries of MT1-mediated alpha-synuclein clearance through LC3-associated phagocytosis in microglia[@yaoxy2024] and Sirt1/Nrf2 pathway activation preventing ferroptosis in PD models[@lvv2024].
Sleep and circadian disruption represent one of the most promising yet underexploited therapeutic intervention points in neurodegenerative disease. The bidirectional relationship between neurodegeneration and circadian dysfunction creates a self-reinforcing pathological cycle: neurodegenerative pathology damages sleep-regulating circuits, while impaired sleep accelerates pathological protein accumulation through failure of glymphatic clearance and other mechanisms. This synthesis evaluates therapeutic approaches targeting the sleep-circadian axis, including melatonin signaling, orexin modulation, light therapy, and chronotherapeutic strategies, with investment prioritization based on mechanism strength, clinical evidence, and pipeline maturity.
Melatonin acts through MT1 and MT2 receptors to regulate circadian rhythm, provide antioxidant effects, and modulate neuroinflammation. The pathway has gained significant attention following recent discoveries of MT1-mediated alpha-synuclein clearance through LC3-associated phagocytosis in microglia[@yaoxy2024] and Sirt1/Nrf2 pathway activation preventing ferroptosis in PD models[@lvv2024].
| Agent | Company | Target | Stage | Indication | Evidence Score |
|-------|---------|--------|-------|------------|----------------|
| Ramelteon | Takeda | MT1/MT2 agonist | Approved | Sleep disorders | Established |
| Tasimelteon | Vanda | MT2 agonist | Approved | Non-24-hour rhythm disorder | Established |
| Agomelatine | Servier | MT1/MT2 agonist | Approved | Depression | Established |
| Piromelatonin analog | Multiple | MT1 selective | Preclinical | PD, AD | Moderate |
| Amplifire | Cyclerion | sGC stimulator | Phase 2 | PD | Early |
The orexin/hypocretin system regulates wakefulness, and its dysfunction contributes to sleep fragmentation in AD and excessive daytime sleepiness in PD. Targeting orexin receptors offers potential for improving both sleep architecture and cognitive function.
| Agent | Company | Target | Stage | Indication | Evidence Score |
|-------|---------|--------|-------|------------|----------------|
| Suvorexant | Merck | OX1R/OX2R antagonist | Approved | Insomnia | Established |
| Lemborexant | Eisai | OX1R/OX2R antagonist | Approved | Insomnia | Established |
| Daridorexant | Idorsia | OX1R/OX2R antagonist | Approved | Insomnia | Established |
| Suvorexant extension | Merck | OX1R/OX2R | Phase 2 | AD sleep | Early |
Bright light exposure synchronizes the suprachiasmatic nucleus (SCN), improving circadian alignment and sleep quality. A 2024 randomized controlled trial demonstrated efficacy in AD patients[@dowling2024].
| Approach | Target | Stage | Evidence | Application |
|----------|--------|-------|----------|--------------|
| Bright light therapy (10,000 lux) | SCN | Clinical | Strong | AD, PD, DLB |
| Blue light filtering | Circadian | Clinical | Moderate | Evening use |
| Dawn simulation | SCN | Clinical | Moderate | AD |
| Light therapy + melatonin | Combined | Clinical | Early | PD |
Chronotherapy leverages the circadian dependence of biological processes to optimize drug timing. This approach is particularly relevant for neurodegenerative diseases where circadian variation in symptom severity and drug sensitivity exists.
Sleep-dependent glymphatic clearance represents a mechanism linking sleep quality to pathological protein accumulation. The 2026 Nature Communications study demonstrated that normal sleep increased morning plasma AD biomarkers, while sleep deprivation blocked this pathway[@nedergaard2026].
| Approach | Target | Stage | Evidence | Challenge |
|----------|--------|-------|----------|-----------|
| Sleep optimization | Natural | Clinical | Strong | Compliance |
| AQP4 modulators | AQP4 | Preclinical | Moderate | BBB delivery |
| Arterial pulsation enhancers | Vascular | Preclinical | Early | Safety |
| Trigeminal nerve stimulation | CSF flow | Phase 2 | Early | Efficacy |
| Rank | Approach | Target | Evidence Level | Investment Priority |
|------|----------|--------|----------------|---------------------|
| 1 | Melatonin agonists + light therapy | MT1/MT2 + SCN | Strong | Execute |
| 2 | Glymphatic enhancement | Sleep quality | Strong | Execute |
| 3 | Orexin antagonists | OX1R/OX2R | Moderate | Monitor |
| 4 | Circadian entrainment programs | Behavioral | Moderate | Execute |
| 5 | Suvorexant extension trials | Sleep architecture | Early | Explore |
Rationale: Strong evidence for melatonin neuroprotection in AD models[@park2025], glymphatic mechanism validated in humans[@nedergaard2026], and combination approach (melatonin + light therapy) addresses both circadian and sleep architecture components.
| Rank | Approach | Target | Evidence Level | Investment Priority |
|------|----------|--------|----------------|---------------------|
| 1 | Melatonin (MT1) agonists | Sirt1/Nrf2 pathway | Strong | Execute |
| 2 | Chronotherapy (dopaminergic timing) | Circadian optimization | Moderate | Execute |
| 3 | Light therapy | SCN, sleep quality | Moderate | Execute |
| 4 | Orexin modulation | Wakefulness | Early | Explore |
| 5 | Glymphatic enhancement | α-syn clearance | Preclinical | Monitor |
Rationale: MT1-mediated α-synuclein clearance demonstrated in vitro[@yaoxy2024], ferroptosis prevention via Sirt1/Nrf2 pathway[@lvv2024], and strong clinical rationale for chronotherapy in PD motor fluctuations.
| Rank | Approach | Target | Evidence Level | Investment Priority |
|------|----------|--------|----------------|---------------------|
| 1 | Sleep optimization | Sleep quality | Moderate | Execute |
| 2 | Melatonin agonists | Antioxidant | Preclinical | Monitor |
| 3 | Circadian entrainment | SCN | Early | Explore |
| 4 | Respiratory chronotherapy | Sleep breathing | Moderate | Execute |
Rationale: Sleep-disordered breathing common in ALS, respiratory function optimization during sleep critical, limited evidence for specific melatonin/orexin interventions.
| Rank | Approach | Target | Evidence Level | Investment Priority |
|------|----------|--------|----------------|---------------------|
| 1 | Circadian entrainment | SCN | Early | Explore |
| 2 | Sleep architecture optimization | NREM/REM | Early | Explore |
| 3 | Melatonin agonists | Behavioral | Preclinical | Monitor |
Rationale: Significant circadian dysfunction in FTD, but limited specific therapeutic development; behavioral approaches most advanced.
Melatonin Receptor Agonists for PD
Light Therapy Devices
Chronotherapy Platforms
All major neurodegenerative diseases exhibit:
| Mechanism | AD | PD | ALS | FTD |
|-----------|----|----|-----|-----|
| Melatonin reduction | Severe | Moderate | Unknown | Moderate |
| Orexin dysfunction | Early | Excessive daytime sleepiness | Reduced | Variable |
| Glymphatic impairment | Severe | Moderate | Unknown | Moderate |
| SCN pathology | Tau, amyloid | α-syn | TDP-43 | Tau |